Cargando…
Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bi...
Autores principales: | Moreno, R., Rojas, L. A., Villellas, Felip Vilardell, Soriano, Vanessa Cervera, García-Castro, J., Fajardo, C. A., Alemany, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525077/ https://www.ncbi.nlm.nih.gov/pubmed/28781596 http://dx.doi.org/10.1155/2017/3615729 |
Ejemplares similares
-
Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model
por: Rincón, Esther, et al.
Publicado: (2017) -
Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy
por: Mahasa, Khaphetsi Joseph, et al.
Publicado: (2020) -
Oncolytic Adenoviruses in Cancer Treatment
por: Alemany, Ramon
Publicado: (2014) -
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
por: Santos, Joao, et al.
Publicado: (2021) -
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager
por: de Sostoa, Jana, et al.
Publicado: (2019)